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SUMMARY
This work is composed of four studies which focus on different aspects of laryngeal
human papillomavirus (HPV) infection, a condition with a variable and
unpredictable course. Clinically the most important manifestation of laryngeal HPV
infection is laryngeal papillomatosis. Based on case records we evaluated which
symptoms or signs at diagnosis could have prognostic value in adult-onset laryngeal
papillomatosis. Two risk factors for frequent laryngeal procedures were found:
young age at the onset of papilloma and a lesion extending to the anterior third of
the vocal folds. As regards the recurrence of disease, the classical division of
adult-onset laryngeal papillomatosis into solitary and multiple types was not found
to be clinically relevant.
Immunological mechanisms which affect the course of laryngeal papillomatosis are
not well understood. To elucidate the role of immunogenetic risk factors we
investigated HLA associations of adult-onset laryngeal papilloma patients by
polymerase chain reaction (PCR)-based methods. No differences in DQA1 or DQB1
frequencies appeared between the patients as a group and the reference population.
A suggestive association was found between the DQB1*0501 allele and the latest
HPV-negative laryngeal biopsy. Those patients without detectable HPV DNA had
undergone fewer laryngomicroscopies than those whose biopsy contained HPV
DNA. The former patient group was also older than the latter. Earlier, the
DQB1*0501 allele was reported to be protective against cervical cancer, another
HPV-associated disease.
Genital HPV infection is known to give rise to the humoral immune response, but in
laryngeal papillornatosis HPV antibody production has not been widely
investigated. In our series, HPV 6 and HPV 16 antibodies were equally frequent in
patients  and controls,  with HPV 11 antibodies more frequent in patients. However,
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no such difference in HPV 11 antibodies appeared between male patients and
controls. In contrast, female patients had HPV 11 antibodies more often than did
male patients or female controls. Female patients also had a high prevalence of
cytological or histological signs of genital HPV infection, which indicates their need
for gynecological examination. Based on our results, serum HPV antibodies are not
clinically relevant in adult-onset laryngeal papillomatosis and may be induced by
concomitant genital HPV infection.
For further studies concerning mechanisms of laryngeal HPV infection, we created a
novel experimental model which is based on the supportive effects of papilloma-
patient laryngeal fibroblasts (PPLF) on HPV-infected laryngeal epithelial cells in
vitro. HPV-positive laryngeal biopsies were first cultured as a monolayer in which
irradiated PPLF served as feeder cells. When these fourth- or fifth-passage epithelial
cells were transferred, to allow growth on an organotypic growth base (collagen
raft) containing unirradiated PPLF, they grew as a multilayer. This layer showed
cytological features typical of HPV infection. Based on in situ hybridization, the
original biopsy sections and epithelial cells from each monolayer passage, as well as
the collagen raft sections, contained HPV DNA. The monolayer cell culture and the
collagen raft, the latter providing differentiation-promoting effects, appears to
facilitate maintenance of HPV-infected cells and of the viral genome.
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INTRODUCTION
The most important clinical manifestation of laryngeal HW infection is laryngeal
papillomatosis, a disease with often relapsing verrucous epithelial tumors. It causes
hoarseness and sometimes even airway obstruction; especially in children, spread to
the lower respiratory tract is possible. Clinically the disease is divided into adult-
onset and juvenile-onset forms (Lindeberg et al., 1986). Laryngeal papillornatosis
has a potential for malignant transformation, which occurs in 3 to 7% of the patients
(Gaylis and Hayden, 1991; Lie et al., 1994). HPV is also associated with laryngeal
carcinogenesis without pre-existing clinical papillomatosis but is considered more
likely to act as a co-factor than a causative agent (Chang et al., 1992). Moreover,
HPV DNA is commonly detected by PCR in macroscopically normal laryngeal
mucosa, and in benign laryngeal lesions lacking histological features of HPV
infection (Nunez et al., 1994a; Rihkarten et al., 1994).
Laryngeal HPV infection is not very well characterized. The means of
transmission. are uncertain, the course of the disease unpredictable, and despite its
viral etiology the treatment is based on surgery. Lack of a good experimental
model and the difficulty in producing virions have hindered in vitro studies. Before
effective prevention and treatment of the disease become available, more
knowledge is needed about HPV, the mechanisms by which the virus is acting in
the larynx, and the characteristics of the affected individuals. The aims of this
study were therefore to discover factors which may affect the susceptibility to or
the course of the disease and to develop an experimental model of laryngeal HPV
infection.
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Human papillomavirus
Human papillomavirus (HPV), which belongs to the Papovaviridae family, is a
small oncogenic DNA virus which infects epithelial cells. Besides laryngeal
papillomas (Lack et al., 1980; Mounts et al., 1982; Gissmann et al., 1983), it also
causes anogenital condylomas (Gissmann and zur Hausen, 1980; Gissmann et al.,
1984), skin warts (Strauss et al., 1949; Pfister et al., 1979), skin cancer in patients
with epidermodysplasia verruciformis (Orth et al., 1978), and cervical carcinoma
(zur Hausen, 1976; Bosch et al., 1995). The structure and composition of the virus
was demonstrated by electron microscopy in human warts (Strauss et al., 1949), and
supercoiled DNA was identified in HPV preparations (Crawford and Crawford,
1963). The existence of different HPV types was demonstrated by the discovery that
plantar wart virus complementary RNA did not hybridize with all viral warts and
with condyloma DNA (zur Hausen, 1974). This was followed by identification of
HPV subtypes (Gissmann and zur Hausen, 1976), and isolation of several new HPV
types (Gissmann et al., 1977; Orth et al., 1977, Orth et al., 1978). Nearly 100
genotypes of HPV, many of which are known to be associated with either benign or
malignant tumors, have been characterized (Favre et al., 1997).
'Ihe papillomavirus genome is a double-stranded, circular structure of 7.9 kb DNA
(Figure 1) which is covered by an icosahedral capsid. All open reading frames are
located on one strand. The function of the HPV genome has been widely
investigated, especially in HPV 16 (McCance, 1994), and the following data are
based on the properties of this HPV genotype. The genome consists of three regions:
an upstream regulatory region (URR), and the two regions named according to the
phase of infection in which they are expressed: the early (E) and the late (L) regions.
12
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HPV 6
HPV 16
Figure 1. Linear presentation of HPV genomes. Data obtained from Cenbank (HPV
6 X00203, HPV 16 K02718).
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Little is known about the interaction of HPVs with their host cells. URR harbors
several regulatory sequences such as binding sites for transcriptional activators
(Gloss et al., 1987). The major transcriptional promoter of HPV 16 is P97 (Smotkin
and Wettstein, 1986), which is regulated by a keratinocyte-specific enhancer (Cripe
et al., 1987; Gloss et al., 1987). The E region consists of eight genes. The E1 and E2
genes are involved in the replication of the HPV genome (Ustav and Stenlund,
1991; Chiang et al., 1992). The E2 protein has been found to repress DNA
replication by binding to specific E2-binding sites in URR (Romanczuk et al.,
1990). The functions or gene products of E3 and E8 are unknown. The interaction of
E4 protein with host cell intermediate filaments causes their collapse, which may
allow the virions to be more easily released from the nucleus (Doorbar et al., 1991).
Although the mRNA for E4 is detected early in infection, both the mRNA and the
protein accumulate during the late phase. The E4 protein is produced in
differentiated cells of benign tumors, and this is why it is considered a late gene
product (Doorbar et al., 1986; Breitburd et al., 1987). The E5 is a small membrane-
associated hydrophobic protein with transforming activity (McCance, 1994). As
reviewed by Auvinen et al. (1997) the E5 protein enhances cell proliferation and
inhibits the control of cell growth, and it has been shown to be an oncoprotein
(Leechanachai el al., 1992; Pim et al., 1992). The most potent oncoproteins are E6
and E7, which are able to transform epithelial cells in vitro, which leads to
immortalized cultures. They accelerate proliferation of the infected cells by
disturbing the function of the tumor suppressor genes p53 and pRb (retinoblastoma
gene), respectively. The E6 oncoprotein has been shown to bind p53 protein and
cause its degradation through the ubiquitin pathway (Scheffner et al., 1990). The
binding of E7 oncoprotein to hypophosphorylated retinoblastoma protein (pRb)
results in the release of a transcription factor E2F, and subsequent transcriptional
activation of E2F-responsive genes, which is required for entry into the S phase
(Dyson et al., 1989).
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The L region has two genes, L1 and L2, which encode the viral structural proteins:
major and minor capsid proteins, respectively. The L1 gene in particular is highly
conserved between HPV types, which means that antibodies against one HPV type
are often cross-reactive with another (McCance, 1994).
HPVs infect basal cells which are the only dividing cells of the epithelium. The
viral particles are bound to cell surface receptors, enter the cell, and are transported
to the nucleus, where the viral genome is released, and the replication takes place.
HPVs can cause either a productive infection in which the late genes are expressed
and virions are produced or a non-productive infection in which only some early
genes are expressed but no viral production occurs. Productive infection does not
lead to host cell lysis, and superficial keratinocytes which contain virus are
eliminated by shedding (Breitburd et al., 1996).
Classification of papillomavirus types is based on host specificity, and on homology
to other papillomaviruses at the genomic level (Delius and Hoftnann, 1994). The
percentage of non~identical nucleotides within the L1 open reading frame leads to a
new virus type if it is more than 10%, if 2 to 10%, leads to a subtype within the
same virus type, and if less than 2%, leads to a variant.
Laryngeal HPV infection
HPV DNA in laryngeal mucosa without clinical papillomatosis
Although the most important clinical manifestation of laryngeal HPV infection is
laryngeal papillomatosis, HPV DNA has been found also in macroscopically
normal- appearing laryngeal mucosa: the incidence of HPV detected by PCR in
macroscopically  normal   upper   respiratory   mucosa  seems   to  be   around  20%.
15
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Unselected post-mortem biopsies of the laryngeal mucosa were HI'V-positive in
25% (Nunez et al., 1994a) and of the hypopharyngeal mucosa in 18% (Nunez et al.,
1994b) of the cases. Vocal cord nodules and polyps harbor HPV 6/11 DNA in 23%
of the patients (Rihkanen et al., 1994).
The role of HPV in laryngeal carcinogenesis is still unclear. In carcinomas without
pre-existing clinical papillomatosis, HPV DNA is detected by PCR in between 8%
and 54% of the cases (Perez-Ayala et al., 1990; Brandwein et al., 1993;
Garcia-Milian et al., 1998). In verrucous carcinoma, a rare, well-differentiated
variant of squamous carcinoma with a low malignant potential, HPV DNA has been
detected in 45% of the cases (Fliss et al., 1994). Studies of precancerous laryngeal
lesions do not support the oncogenic cofactor role of HPV in laryngeal
carcinogenesis (Fouret et al., 1995; Lindeberg and Krogdahl, 1997); at the present
level of knowledge, the issue remains obscure.
Laryngeal papillomatosis
1. Clinical features
The viral etiology of laryngeal papillomatosis was first described by Ullman (1923).
Although the disease is rare, the incidence for example in a Danish subpopulation
being only 3.8 /million/ year (Lindeberg and Elbrond, 1990), papilloma is the most
common benign laryngeal neoplasm, accounting for up to 84% of benign tumors
(Strong et al., 1979; Jones et al., 1984). The main symptom of the disease is
hoarseness, but airway obstruction is sometimes present as well (Lindeberg and
Elbrond, 1989). Laryngeal papillomatosis is clinically divided into adult-onset and
juvenile-onset forms (Lindeberg et al., 1986). Especially in children, the disease can
be life-threatening; it can disseminate throughout the tracheobronchial tree and end
in     pulmonary     papillomatosis     with    uncontrollable     fatal   chest    infection
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(Padayachee and Prescott, 1993). The means of transmission are in part unknown
although adult-onset disease is related to possible orogenital spread, and juvenile-
onset to transmission of the infection from mother's HPV-infected genital tract to
the child at the time of birth (Kashima et al., 1992).
Depending on the authors, laryngeal papillomatosis is considered to be adult-onset
if the patient is older than 16 to 20 years at diagnosis (Lindeberg et al., 1986;
Corbitt et al., 1988). Unlike the juvenile form with a sex ratio about equal
(Lindeberg and Elbrond, 1989; Padayachee and Prescott, 1993), in the adult-onset
disease mostly males are affected: the male-to-female ratio has been 2:1 to 4:1
(Capper et al., 1983; Lindeberg and Elbrønd, 1989). HPV 6 and HPV 11 virus
types are most commonly found in laryngeal papilloma lesions (Bryan et al., 1990;
Smith et al., 1993; Gale et al., 1994; Pou et al., 1995), the former being even more
common in adult-onset lesions than is the latter (Corbitt et al., 1988). The most
typical site of infection at diagnosis is the vocal folds (Capper et al., 1983). The
course of the disease is unpredictable: some patients recover after one laryngeal
procedure, while the others run a relapsing course. One reason for this could be
that HPV DNA is detected both in biopsies from uninvolved sites and from
patients in remission (Steinberg et al., 1983; Abramson et al., 1987, Rihkanen et
al., 1993). Malignant transformation of laryngeal papillomas is a rare event, and
occurs only in 3% to 7% of the patients (Gaylis and Hayden, 1991; Lie et al.,
1994). Earlier, one of the treatments used for these patients was irradiation therapy,
which seemed to increase the risk for malignant transformation, but malignant
transformation may also take place with no history of irradiation (Solomon et al.,
1985), and both low-risk and high-risk HPV types are involved (Lindeberg et al.,
1989; Doyle et al., 1994). Smoking is also a potential cofactor in the conversion of
laryngeal papilloma to carcinoma (Kashima et al., 1996).
17
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2. Treatment and prevention
The goal of the treatment is to ensure a safe airway and the best possible quality of
voice. The many different medical, surgical, and immunological procedures used for
the treatment of laryngeal papillornatosis have been reviewed by Clark and
MacKenzie (1996). However, even at present the treatment is based on surgical
removal of lesions by carbon dioxide (CO2)-laser, a method introduced as early as
the 1970's (Strong et al., 1973, 1976) or with a shaver, which is far from optimal
because of the viral etiology of the disease. Alpha-interferon treatment is sometimes
given, especially to children, because their disease is often more aggressive, with
frequent relapses and possible spread to the lower parts of the respiratory tract; but
despite the treatment, relapses are common (Haglund et al., 1981; Schuurman and
Van Den Broek, 1986; Steinberg et al., 1988; Leventhal et al., 1991). Promising
preliminary results have been reported in the treatment of severe laryngeal
papillomatosis with intralesional cidofovir injections (Snoeck et al., 1998) or flash
pump dye laser (Bower et al., 1998).
Prevention of laryngeal HPV infection is difficult because the means of
transmission are not exactly known. Vaccines which are based on L1 capsid proteins
produced in non-mammalian cells and self-assembled into virus-like particles
(VLPs) provide potential means of preventing genital HPV infection and the
subsequent development of cervical cancer (Schiller and Lowy, 1996). A polyvalent
genital HPV vaccine that includes VLPs of low-risk as well as high-risk types (HPV
6, 16, 18, 31, 45) may be able to prevent recurrent respiratory papillomatosis as
well, if the original source of the virus in this disease is the genital HPV infection.
Adding only one low-risk type VLP to the vaccine may be sufficient, because of the
possible cross-protection against HIV 11 (Roden et al., 1996).
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3. Cellular and humoral immunity
Typical features of BPV infections are transition from latent infection to clinically
recognized disease, the regression of benign or premalignant HIV-induced tumors,
and the appearance of malignant HPV-harboring cells (Breitburd et al., 1996).
Immunological events are possible reasons for these features. Moreover, such events
may influence the variable course of laryngeal papillomatosis and the infrequency of
the disease, when compared to the frequency of HPV DNA detected in
macroscopically normal laryngeal mucosa. Cellular immunity is of major
importance for the clearance of infections caused by HPVs, although direct
exposure of the virus proteins to immunocompetent cells does not occur (Gissmann,
1996). This is in line with the fact that HIV-related cancers are more common in
immunocompromised individuals (Benton et al., 1992; Dillner, 1992; Arends et al.,
1997; Palefsky, 1997). Class I and class II HLA molecules present HI'V-derived
peptides to cytotoxic T lymphocytes (CTL) or T helper lymphocytes (Th). Infiltrates
of CD4-positive Ths or CD8-positive CTLs and macrophages have been observed in
spontaneously regressing HPV lesions (Iwatsuki et al., 1986; Tay et al., 1987;
Coleman et al., 1994; Stanley et al., 1994). HIV-harboring epithelial cells may
modify the immune response by secreting cytokines (Woodworth and Simpson,
1993) and by showing abnormal expression of HLA class I and class II antigens
(Stern, 1996)
Down-regulation of HLA class I expression and up-regulation of HLA class II
expression are characteristic events in cervical HPV infections. HLA associations
have been investigated, especially in cervical intra-epithelial neoplasia and cervical
cancer (Apple et al., 1994; Odunsi et al., 1996), whereas in laryngeal papillomatosis
they are poorly verified. Bonagura et al. (Bonagura et al., 1994), in a series of 16
adult- and juvenile-onset laryngeal papilloma patients, found the HLA DQw3
phenotype  to  be enriched.  They  found also  HLA  class I expression  in papilloma
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tumor sections to be reduced compared with that in normal laryngeal epithelium,
while in HLA class II expression no difference was observed. In natural killer cell
activity no specific alteration in laryngeal papilloma patients appeared (Naiman et
al., 1984).
Humoral immune defects do not seem to predispose to HPV infections (Schiller and
Okun, 1996). Several different HPV antigens have been used to measure serological
anti-FIPV reactivity: bacterially expressed fusion-proteins containing HPV open
reading frames (jenison et al., 1988; Jochmus-Kudielka et al., 1989), synthetic
peptides (Dillner et al., 1989a; Müller et al., 1990), denatured bovine
papillomavirus virions, HPV virions obtained from clinical samples in the case of
HPV 1, HPV virions produced in an in vivo-mouse model, and assembled VLPs -
also called capsids (Cubie and Norval, 1988; Dillner et al., 1989b; Christensen et
al., 1992). A serological assay based on VLPs is the most extensively used and
validated method for type-specific serodiagnosis of HPV infection, and most studies
on HPV antibody response have focused on genital HPV infection (Kirnbauer et al.,
1994; Wikström et al., 1995a; Eisernann et al., 1996; Kjellberg et al., 1999).
Antibodies to HPV 11 virions have been detected mainly in juvenile-onset laryngeal
papillomatosis (Bonnez et al., 1992; Christensen et al., 1992). Only one report
exists on adult-onset laryngeal papilloma patients, and it included only 15 patients
and employed a first-generation HPV serology assay with limited HPV
type-specificity (Tachezy et al., 1994).
Relation between laryngeal and genital HPV infection
Both low-risk and high-risk HPV types are involved in genital HPV infection: HPV
6 and 11 are typically  found in condylomas  and HPV 16, 18, 31, and 45 in cervical
20
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cancer. The latter four comprise 80% of the HPV types detected in cervical cancers
(Bosch et al., 1995).
Genital HPV infection is known to be transmitted in sexual intercourse. In the
1950's the relevance of maternal condyloma to laryngeal papilloma was already
being noted (Hajek, 1956). A history of maternal condyloma was found in more
than 30% of mothers bearing children with juvenile-onset laryngeal papillomatosis
(Quick et al., 1980). Juvenile-onset disease occurs most commonly in first-born
infants delivered vaginally to young mothers with genital condylomas (Kashima et
al., 1992), with cases of juvenile-onset laryngeal papillomatosis being rare in
caesarean-delivered children (Shah et al., 1986). On the other hand, because HPV
DNA has been detected even in amniotic fluid (Armbruster-Moraes et al., 1994),
and because the overall risk of papillomatosis developing in the offspring born to a
mother with genital HPV infection is only 1 in 32 (Kashima et al., 1996), caesarean
delivery for expectant mothers with genital condylomas is thus not routinely
recommended.
Transmission of adult-onset laryngeal papillomatosis via orogenital spread is
commonly mentioned, but clear evidence for this does not exist. The idea that
adult-onset disease is spread by orogenital contact is based on the fact that both
laryngeal papillomatosis and genital condylomas harbor the same virus types 6 and
11. Type 6 is, however, even more frequently found both in adult-onset laryngeal
papillomatosis and in genital condylomas (Corbitt et al., 1988; Greer et al., 1990).
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In vitro models of HPV infection
The major problem in the in vitro studies of HPV infection is that the virus does not
replicate in cell culture. Differentiation of the epithelium, a critical point for
expression of the complete viral life cycle, cannot yet be fully duplicated in vitro
(Gissmann, 1994). At present, the basic technique most widely used for in vitro
studies of HPVs was originally created by Asselineau and Pruni6ras (1984). As
described briefly in a review by Meyers and Laiminis (1992), fibroblasts mixed with
medium and type I collagen at 0 ºC to 4 ºC are incubated at +37 ºC until the solution
solidifies and forms a lattice (collagen raft) which is used as a dermal equivalent.
Epithelial cells are seeded on top of the raft and allowed to attach and form a
monolayer. The raft is placed on a metal grid, and the epithelial cells stratify and
differentiate at the air-medium interface during two or three weeks. This artificial
epithelium resembles its in vivo counterpart well, with only minor differences found
in the morphology of the basal keratinocytes and in the distribution of few
keratinocyte-specific antigens. Differences have been detected for example in the
expression of cytokeratins K1 and K2 (Kopan et al., 1987), but by varying the
growth conditions and the collagen matrix and the fibroblasts used for the
experiments, such discrepancies may be diminished.
Efforts to develop cell culture models to study HPV replication have involved
immortalizing of primary squamous epithelial cells or culturing them directly from
papillomatous lesions. Immortalization of epithelial cells with HPV 16 and 18 DNA
(Dürst et al., 1987; Pirisi et al., 1987; Woodworth et al., 1988) results in the
integration of the viral genome into the host cell DNA. When epithelial cells are
transfected with HPV 11, which does not integrate, episomal viral replication is
detected, but only a portion of the virus reaching the nucleus undergoes replication
(Auborn et al., 1996).
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For the homeostatic equilibrium of epithelial cells, epithelial-mesenchymal
interactions are important (Cunha et al., 1986; Streuli et al., 1991; Smola et al.,
1993), and to utilize the stimulating effect of mesenchymal tissue, HIV-infected
epithelial cells have been cultured in nude mice and on an organotypic growth base
(collagen raft). The first successful propagation of HPVs in the laboratory was
provided by Kreider and colleagues who incubated fragments of human neonatal
foreskin with an extract from an HPV 11-containing vulvar condyloma, and after
incubation grafted them under the renal capsule of nude mice. The grafts developed
into condylomatous cysts from which virions could be extracted and used to initiate
new cycles of cyst formation (Kreider et al., 1987). HPV 31 virions have been
produced in collagen rafts after addition of a phorbol ester to the medium (Meyers et
al., 1992), and when pieces of condylomas containing HPV 11 were explanted on
collagen rafts, HPV production was observed (Dollard et al., 1992). Moreover,
when examined in collagen rafts, epithelial cells transfected with HPV 16 displayed
an altered pattern of differentiation (McCance et al., 1988; Zheng et al., 1994).
However, it is impossible thus far to produce reasonable amounts of virions by the
methods available.
The model for culturing normal human epithelial cells was described by Reinwald
and Green (1975). These cultures included a feeder layer of lethally irradiated
mouse fibroblasts which supported the growth of epithelial cells and inhibited that
of fibroblasts. Moreover, epithelial cells have been successfully cultured imbedded
in collagen gels (Yang et al., 1980). A method that allows laryngeal papilloma-
derived squamous epithelial cells containing HPV 6 or HPV 11 DNA to be cultured
has been introduced by Steinberg and colleagues (1982). Epithelial cells were grown
in tissue culture in a hydrated collagen gel including Nutrient Mixture F12
supplemented with 15% fetal calf serum and 10 µg/rid hydrocortisone. The cells
remained viable in culture for more than 6 months and could be serially transferred
two  to four times  before senescence.  However,  the viral  DNA is rapidly lost from
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the cell cultures with passaging, possibly because the infected cells show a selective
disadvantage in plating efficiency compared with that of uninfected cells
(DiLorenzo et al., 1992).
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The course of laryngeal papillomatosis is variable and unpredictable, and the lack of
an experimental model has hindered in vitro studies. The aims of the study were to:
1. find whether some clinical features at diagnosis can predict the course of
adult-onset laryngeal papillomatosis.
2. investigate the role of HLA DQ alleles in adult-onset laryngeal papillomatosis.
3. investigate whether adult-onset laryngeal papillomatosis induces a humoral
immune response.
Because adult-onset females had HPV 11 antibodies more often than did male
patients or female controls, and they also had often a history of genital
condylomas, further studies investigated whether these female patients' HPV
antibodies could have been of genital origin.
4. develop an experimental model of laryngeal HPV infection.
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Patients and samples
From all case records of patients who were treated at Helsinki University Central
Hospital, Department of Otorhinolaryngology - Head and Neck Surgery during 1975
to 1994 with a diagnosis of benign or undefined laryngeal neoplasm, those with a
histologically confirmed diagnosis of laryngeal papilloma (n=160) were selected. A
schematic presentation of patient selection is shown in Figure 2. The material of the
retrospective work (Study I) included case records of the 74 adultonset patients (age
at diagnosis ≥ 17 years) without malignant transformation whose first laryngeal
procedure was performed at Helsinki University Central Hospital and whose
follow-up exceeded one year. Studies II and III were based on this same adult-onset
laryngeal papilloma patient population without malignant transformation. Of the 113
patients, 43 were excluded: 5 had died, 17 were >80 years old, and 21 did not live in
the hospital district. Of the 70 invited patients 8 did not attend. Thus, 62 patients
filled in a questionnaire and had their larynxes videorecorded. Peripheral blood
lymphocytes and serum samples for HPV antibody assay were drawn, and
lymphocytes were isolated as a source of DNA. The patients' paraffin-embedded
most recent laryngeal biopsies were used for determination of the type of laryngeal
HPV infection by PCR. All female patients were invited for a second visit to an
otorhinolaryngologist, which included also an examination by a gynecologist.
Mouth-wash and mouth-brush samples, Pap smears, and colposcopically directed
cervical biopsies were taken, and a second serum sample was drawn. For the
experimental part of the work (IV), fresh laryngeal tissue biopsies were obtained
from 30 laryngomicroscopies (corresponding to 15 adult-onset and 2 juvenile-onset
laryngeal papilloma patients) and of one total laryngectomy (from a patient with an
esophageal carcinoma. infiltrating the trachea). These patients too, were treated at
Helsinki  University  Central  Hospital.  The  HIV-positive  epithelial cells  grown on
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collagen rafts (IV) were taken from papilloma tumors of two adult-onset patients
and one juvenileonset patient and of normal-appearing laryngeal mucosa (false
vocal fold) of an esophageal carcinoma patient.
Benign or undefined laryngeal tumors
treated at HUCH 1975-1994
Histology of laryngeal papilloma
n = 160
Juvenile-onset patients  Adullt-onset patients Patients later developing
n =34 (≥17 yrs) n=113 laryngeal carcinoma*
n=13
Exclusion criteria: Exclusion criteria:
Diagnostic Age >80 yrs
laryngomicroscopy at 
hospitals other than Deceased
HUCH
Not residing in the
Follow-up <1 yr hospital district
Retrospective study (I) based on Prospective studies (II, III) based
case records (n = 74) on examined patients (n = 62)
Figure 2. Schematic presentation of patient selection for Studies I, II, and, III.
*3 of these patients had a clinical papillomatosis which ended in malignancy, 10
laryng.eal carcinoma patients' histology of laryngeal papilloma was confirmed. in
sporadic biopsies.
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Our reference populations were, in the HLA studies, 93 cadaver kidney donors
(Partanen and Westman, 1997), and in the HPV antibody assay, 53 age- and sex-
matched (13 females, 40 males) anonymous blood donors. For five male and two
female patients of advanced age it was impossible to find age-matched blood donor
controls. Informed consent was obtained from all patients in this study. The human
experimentation guidelines of Helsinki University Central Hospital were followed,
and the study was approved by the institutional ethics committees of the Department
of Otorhinolaryngology - Head and Neck Surgery and the Department of Obstetrics
and Gynecology.
Cell cultures
The human cells used for this work were grown from fresh tissue biopsies. They
were cultured first in monolayers in which irradiated (XR) fibroblasts (dose of
irradiation 6000 rad, radiation source Ce137) served as feeder cells. Onto each 8.7
cm2 plate (Greiner, Frickenhausen, Germany) we seeded 2x105 irradiated
fibroblasts. The biopsies were cut into small pieces and allowed to grow first on
these irradiated mouse fibroblasts (3T3-J2, kindly provided by Dr. Michele De
Luca, Genoa, Italy). In these cultures, papilloma-patient laryngeal fibroblasts (PPLF)
took over, and because of the poor support provided by mouse 3T3-J2 cells to
human HPV-positive epithelial cells, PPLF were in further experiments irradiated
(PPL17-XR) and used as feeder cells. The fibroblasts were cultured in Dulbeeco's
modified Eagle's medium (DMEM) supplemented with 10% heatinactivated fetal
calf serum (FCS), 2mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml
streptomycin (henceforth referred to as supplemented DMEM), and the medium was
changed three times a week. The patient who supplied these laryngeal fibroblasts
was a 24-year-old male with adult-onset disease of a low-risk HPV type. The
HPV-infected  epithelial  cells were then  cultured  in a  monolayer cell  culture until
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the fourth or fifth passage without loss of HPV DNA, and were then transferred to
allow growth on collagen rafts.
1. Monolayer cell cultures
The biopsies were brought to the laboratory in supplemented DMEM, sectioned into
small pieces, and allowed to grow on irradiated fibroblasts. Irrespective of the type
of irradiated fibroblasts used, their growth medium, with or without epithelial cells,
was supplemented DMEM further supplemented with 5 µg/ml insulin (Sigma, St.
Louis, MO), 5 µg/ml transferrin (Sigma) 400 ng/ml hydrocortisone (Sigma), 10-10 M
cholera enterotoxin (ICN, Aurora, OH), and 10 ng/ml epidermal growth factor
(EG17) (Austral Biologicals, San Ramon, CA). This medium and the method used
to propagate the epithelial cells is modified from that of Rheinwald and Green
(1977). The medium was changed three times a week. Before the fibroblasts were
seeded, coverslips coated with 1% 3-aminopropyltriethoxysilane (Sigma) were
placed on the culture dishes to obtain cells from monolayers for in situ
hybridization. At each passage, the coverslips were removed, rinsed in
phosphate-buffered saline, pH 7.4, and fixed in cold acetone at -20 ºC for 10 min.
The cultures were maintained in a 5%-CO2 incubator at 37 ºC, and if not used for
experiments at once, the cells were frozen in growth medium containing 10%
dimethyl sulfoxide (Merck, Darmstadt, Germany) at -70 ºC. On average, the cells
reached the fourth passage on the 28th day of culture.
2. Organotypic cell cultures (collagen rafts)
The method of preparing collagen rafts has been described in detail earlier
(Asselineau and Pruniéras. 1984; Zheng et al., 1994). Twelve-well plates (4 cm2;
Costar, Cambridge, UK) were precoated with 1.6% sterile agarose in 2 x MEM
containing  glutamine,  and  antibiotics  to prevent  the fibroblasts  from  adhering to
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the plates. The fibroblasts were suspended in 2 x MEM containing 20% FCS,
glutamine, and antibiotics and mixed with type I collagen (Rat tail; UBI, Lake
Placid, NY). For each raft we used 4 x 105 PPLF fibroblasts; the final collagen
concentration was 0.7 mg/ml. The total volume of the mixture of cells and collagen
was 2.5 ml per well. The plates were then cultured in a 5%-CO2 incubator at 37 ºC
for one day. After that, the shrunken collagen gels were transferred to a 24-well
plate (1.75 cm2; Greiner) into which the fourth or fifth passage HPV-positive
epithelial cells (2x105 cells from 90% confluent culture dishes) were seeded. The
next day the collagen rafts were transferred onto metal grids and cultured at the
air-medium interface for two weeks. The medium (DMEM with 10% FCS,
antibiotics, glutamine, insulin, hydrocortisone, transferrin, cholera toxin, and EGF)
was changed three times a week. The rafts were then fixed in formalin, embedded in
paraffin, and sectioned for detection of HPV DNA. Staining of sections with
hematoxylin and eosin was also performed for histological evaluation.
In situ hybridization
Both the tissue biopsies from the larynx and the collagen rafts were embedded in
paraffin and sectioned. From these sections, as well as from acetone-fixed cells from
the monolayers, HPV-DNA was tested by in situ hybridization (HPV in situ
Screening Test®; Biohit, Helsinki, Finland). The details of this method have been
described by Syrjdnen (1990). Five-µm sections were deparaffinized, digested with
proteinase, and hybridized with a cocktail of probes (corresponding to 32 HPV
types) at 37 ºC overnight. The biotinylated hybrids were detected by alkaline
phosphatase conjugated to streptavidin, with 5-bromo-4-chloro-3-indoylphosphate
as substrate and nitroblue-tetrazolium as chromogen. The incubation time in the
substrate solution was 3 hours for paraffin-embedded sections and 0.5 hour for cell
samples.  Fixed  human uterine  cervical  carcinoma CaSki cells (ATCC CRL-1550;
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American Type Culture Collection, Rockville, MD) which contained HPV 16 DNA
were used as positive controls when biotinylated HPV DNA probes Were added,
and as negative controls when biotinylated pBR322 control probes were used for
hybridization. Moreover, our own additional controls included paraffin-embedded
biopsies of ovarian tube (negative controls), uterine cervix with condyloma and
dysplasia, and a laryngeal papilloma known to be of low-risk HPV-type (positive
controls).
DNA extraction
DNA from fresh samples and from deparaffinized tissue samples was extracted by
standard phenol-chloroform methods (Sambrook et al., 1988).
Chemiluminescent molecular hybridization assay
Detection of HPV DNA in PPLF cell cultures and in original tissue biopsies (IV)
was performed by the Hybrid CaptureTM System (Digene Diagnostics, Beltsville,
MD). This sandwich-capture molecular hybridization assay which classifies the
samples according to the virus type present (low-risk types 6, 11, 42, 43, 44, or
high/intermediate-risk types 16,18, 31, 35,45, 51, 52, 56) utilizes chemiluminescent
detection: the principles of the technique have been described elsewhere (Rothrock,
1992). In short, the specific HPV RNA probe cocktail of the test hybridizes with
specimens containing the target DNA. A tube surface coated with anti-RNA-DNA,
antibodies captures the RNA-DNA hybrid. An anti-hybrid antibody conjugated to
alkaline phosphatase is then reacted with the hybrid and detected with a
chemiluminescent substrate. The bound alkaline phosphatase cleaves the substrate,
and  the  light  which  it  emits  is measured on a  luminometer as relative light units,
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with amount of target DNA in the specimen proportional to intensity of light
emitted. Biopsies of 2-5 mm in diameter or cell suspensions containing 1-2 million
cells from a culture dish served as samples. The reported sensitivity of the test is 1
copy/cell, when 1-2 million cells are assayed.
Polymerase chain reaction for detection of β-globin and HPV DNA
For all the paraffin-embedded laryngeal papilloma samples, PCR was performed
both with g-globin primers (Saiki et al., 1985) and with type-specific primers for
HPV 6, 11, and 16 (van den Brule et al., 1989). Specimens negative with type-
specific primers were subjected to PCR with general HPV primers GP5+/6+ (de
Roda Husman et al., 1995). Because of the small quantity of DNA, PCR was
performed in two phases: first 20 cycles and then 35 cycles in which 5 µl of the
former PCR product served as a template. The reaction mixtures contained 1.5 mM
MgCl2, 0.4 µM of each primer, dNTP 0.2 mM each, and 1 U AmpliTaq GoldTM
DNA polymerase (Perkin-Elmer, Roche Molecular Systems, Branchburg, NJ). The
PCR reaction was initiated with a "hot star" (10' +95 ºC) followed by 1' +95 ºC
denaturation, 2' annealing, 1.5' +75 ºC chain elongation, and another 4' +72 ºC
chain-elongation step after the last cycle. The annealing temperature was +40 ºC for
GP5+/6+, +58 ºC for β-globin, HPV 6, and 11 primers, and +62 ºC for HPV 16
primers. All PCR reactions were performed with a PTC-100TM automated PCR
machine (MJ Research, Watertown, MA). For the fresh mouth-washes, mouthbrush,
and cervical biopsy samples (III), PCR was performed with β-globin and GP5+/6+
primers in one phase (40 cycles).
HPV 6 and HPV 11 plasmid DNA (5 ng/reaction) or HPV 6- and HPV 11-positive
laryngeal specimens served as positive controls. Cenomic DNA (5 ng/reaction)
isolated  from SiHa  cells (ATCC HTB-35)  served as  a positive control  in HPV 16
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PCR, and DNA (5 ng/reaction), isolated from an HPV 16-containing cervical
carcinoma biopsy, for GP5+/6+ PCR. Our negative controls were HPV 6-, 11-, and
16-negative laryngeal specimens, respectively, and for GP5+/6+, DNA extracted
from laryngeal fibroblasts of a patient with no known history of HIV-related
disease. Both for paraffin and for water controls, glycogen was added, to serve as a
carrier for possible DNA contamination. Five µl of each PCR product was run in
2% agarose gel which was visualized with ethidium bron-dde, and the products of
HPV-type-specific PCR reactions were transferred to nylon membranes for
detection. The sensitivity of the test was determined by performing PCR with
GP5+/6+ primers on a dilution series of samples containing HPV 11 plasmid DNA.
The test detected 100 ag HPV plasmid DNA corresponding to approximately 12
copies of HPV DNA.
Southern blot hybridization
The PCR products were transferred to Hybond N+ nylon membranes (Amersham
Life Science, Buckinghamshire, UK). These membranes were prehybridized and
hybridized with digoxigenin-labelled oligonucleotide probes. The hybrids were
immunologically detected with alkaline phosphatase-conjugated anti-digoxigenin
Fab, fragments (Boehringer Mannheim, Mannheim, Germany), followed by a
chromogenic reaction (4-nitro blue tetrazolium chloride and x-phosphate/5-bromo-
4-chloro-3-indolyl-phosphate, Boehringer Mannheim).
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PCR-based HLA class II typing
The DQA1 alleles were determined as described by Ota et al. (1991). The assay
distinguishes 7 different DQA1 allele-groups, i.e. *0101/2/4, *0103, *02, *03, *04,
*05 and *06. The DQB1 alleles were determined by means of the Inno-Lipa DQB1
reverse-dot blot kit (Innogenetics, NV, Zwijndrecht, Belgium), which detects 25 of
the 26 currently known DQB1 alleles.
HPV serology
HPV antibodies were detected by a standard enzyme immunoassay based on
baculovirus-expressed capsids (Kirnbauer et al., 1994). Purified capsids were
diluted to 50 ng/ml in ice-cold PBS and coated onto EIA plates overnight at +4 ºC.
The plates were blocked with 10% horse serum in PBS for 60' at +37 ºC and
incubated with human serum for 90' at +37 ºC. Bound IgG antibodies were detected
by incubation with a monoclonal antibody against gamma chain (Eurodiagnostics,
Apeldoorn, The Netherlands) for 90' at +37 ºC. Bound monoclonal antibodies were
detected with a goat anti-mouse gamma-chain horseradish-peroxidase conjugate
(Southern Biotechnology, Birmingham, AL). ABTS peroxidase was applied, and the
results were measured as differences in optical density between antigen-coated and
negative control plates reacted with the same serum and developed identically. The
patient and control sera were run simultaneously in the EIA plates. The cut-off level
used to assign seropositivity from absorbance values was pre-assigned and relative
to the same internal standards used in previous studies (Wikström et al., 1995a).
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Statistical analysis
Nonparametric statistical methods were applied to continuous variables (Kruskall-
Wallis test and Mann-Whitney U test, I, II). The differences between groups in HLA
allele and HPV antibody frequencies were tested with Pearson's Chi-square test or
Fisher's exact test (II, III). The latter was used when the number of an expected
value in at least one cell was less than 5.
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Clinical features predicting  the course of adult-onset laryngeal papillomatosis
(I)
A total of 74 patient records with adult-onset disease were evaluated: 57 males
(mean age 44 years at diagnosis, range 20-80) and 17 females (mean age 39 years at
diagnosis, range 21-71 years). The mean follow-up time was 6.2 years (range 1.0-
32.4 years).
The most frequent symptom was dysphonia (84%), but dyspnea (3%) and pain in the
throat (7%) were also occasionally present. The location of the primary lesion
typically extended to the anterior (59%) or middle third (64%) of the vocal folds;
lesions extending to the posterior third (31%) were less common. If a lesion was
found at diagnosis elsewhere in the larynx, the vocal folds were also affected in 67%
of the patients. Lesions covering less than a third of a vocal fold were considered to
be small, and those covering more, large. Most of the patients (62%) each had at
least one large papilloma lesion. Solitary lesions (68%) were more common than
multiple ones.
Laryngeal procedures were performed for each patient on average 5.4 times (range
1-66). Since the year 1985, laser treatment has been available at our clinic, and 50%
of the patients in this series were treated with CO2-laser, solely or combined with
mechanical removal. Interferon treatment was given to four patients. Two
tracheostomas in this series were performed before laser treatment was available.
To investigate which symptoms and signs at diagnosis might predict the course of
the disease, number of laryngeal procedures was chosen as the indication of the
severity of the condition. Patients who underwent 1-2 (seldom relapsing disease),
3-6  (often  relapsing  disease),  or over 6  (very often  relapsing disease)  procedures
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were similar in most respects. No statistically significant differences existed
between these groups in symptoms, size, or number of primary papilloma lesions.
Those 25 patients who had only one small papilloma lesion at diagnosis were
equally distributed among the groups. Two clinical findings predicted the course of
the disease: those with very often relapsing disease were younger (mean age 33.8±
11.5 years) than the others (p < 0.05, Kruskall-Wallis test), and they had a lesion
extending to the anterior third of the vocal folds more often (p< 0.01, Kruskall-
Wallis test) than did the rest of the patients.
HPV type distribution and impact of HLA DQ alleles in adult-onset laryngeal
papillomatosis (II)
Patient description
The male-to-female ratio was three to one: 47 male patients, mean age 53 years
(range, 26-77), and 15 female patients, mean age 48 years (range, 27-71). The mean
follow-up time was 10 years (range, 1-35). No hereditary component was
discovered for the disease, and in otorhinolaryngological examination no HPV-
associated lesions were detected outside the larynx. A laryngeal tumor relapse was
found in 14/62 patients (2 females, 12 males), and in two of these males the relapses
proved, according to subsequent histopathology of the biopsies, to be carcinomas.
HPV types detected
Formalin-fixed paraffin-embedded biopsies were available from 61 of the 62
patients. Of all the specimens, 45 (74%) were amplifiable in our PCR. Most of
these, 20 (33%) were HPV-6 positive, 8 (13%) were HPV 11-positive and 2
harbored  some  other  HPV  type  (Figure 3).  One specimen  was both  HPV 6- and
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HPV 11-positive. No HPV 16- positive samples were detected. The group of
HPV-negative samples and samples not amplifiable in our PCR both comprised 16
samples (26% each). Those with an BPV 6- or HPV 11-positive laryngeal biopsy
did not differ from each other with respect to age, sex, number of laryngeal
procedures performed, or number of relapses found in the clinical examination.
HLA DQ alleles related to HPV type of laryngeal biopsy, and clinical features
No differences in the DQA1 and DQB1 frequencies were detected between patients.
as a group and the reference population. When patients were divided into groups
according to number of laryngeal procedures performed (1 or 2, 3-6, >6), no HLA
association was noticed. Neither did the presence of HPV 6 or HW 11 DNA in the
laryngeal specimen correlate with HLA type. Patients whose latest laryngeal
specimen showed a typical histology of HW infection, but was HPV-negative, had
an increased frequency of the DQB1*0501 allele compared with those whose
laryngeal biopsy was HPV-positive (uncorrected p=0.0053, Pearson's Chi-square
test; Bonferroni corrected, p=0.053) or compared with the reference population
(uncorrected p<0.001, Pearson's Chi-square test; Bonferroni corrected, p=0.002).
These patients had also undergone fewer laryngomicroscopies (mean 2.8; range,
1-17) than those whose biopsy contained HPV DNA (mean 5.7; range, 1-70)
(p=0.003, Kruskall-Wallis test). The former patient group was also older than the
latter at diagnosis (p<0.001, Kruskall-Wallis test).
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                                           1  2   3  4   5   6  7   8   9  10
                  bp
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                  344
                  298
           220/201
Figure 3a. HPV 6- and HPV 11-positive specimens run in agarose gel and stained
with ethidium. bromide. Lanes 1 and 7: DNA molecular-weight marker X
(Boehringer Mannheirn). Lanes 2 through 6: HPV 6-positive PCR products (280
bp). Lanes 8 through 10: HPV 11-positive PCR products (360 bp).
                                   HPV 6           HPV 11
bp bp
320 404
242 320
Figure 3b. Corresponding PCR products transferred to membrane and hybridized.
Left, HPV 6-positive PCR products equivalent to lanes 2 through 6. Right, HPV 11-
positive PCR products equivalent to lanes 8 through 10 in Figure 3a. Markers:
Digoxigenin-labeled DNA molecular-weight marker VIII (Boehringer Marmheim).
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HPV antibody response in adult-onset laryngeal papillomatosis and over-
representation of cytological and histological signs of genital HPV infection in
female patients (Ill)
The patient population in Studies H and III was the same. Serum samples of 60
adult-onset laryngeal papilloma patients and 53 age- and sex-matched controls (13
females and 40 males) were available for HPV 6, 11, and 16 antibody assays. For
five male and two female patients of advanced age, it was not possible to find age-
matched blood-donor controls. HPV 6 and 16 antibodies were equally frequent in
patients and controls (23% vs. 21% and 22% vs. 23%, respectively), with HPV 11
antibodies more frequent in patients (33% vs. 15%, p=0.03, Pearson's Chi-square
test). However, no such difference in HPV 11 antibodies appeared between male
patients and controls. In contrast, female patients had HPV 11 antibodies more often
than did male patients (60% vs. 24%, p=0.01 Pearson's Chi-square test) or female
controls (60% vs. 15%, p=0.02, Pearson's Chi-square test), but there was no
difference in HPV 11 antibodies between female and male controls (15% vs. 15%).
The presence of serum HPV antibodies did not correlate with HPV type in laryngeal
biopsy, with time-interval (less than 1 year, 1-3 years, more than 3 years) between
laryngeal biopsy and serum sampling for HPV antibody assay, with number of
laryngeal procedures, or with relapse detected by clinical examination.
We further studied whether our female patients' HPV 11 antibodies could have been
caused by oral or genital HPV infection. Of the 15 females, 9 attended the thorough
re-examination (see Patients and samples), and 5 of them (56%) had cervical
cytology consistent with an HPV infection; and 3 of them also had histological
features of HPV infection in cervical biopsy. HPV DNA was detected in one
cervical biopsy with general HPV primers. Only three female patients had HPV 11
antibodies in their second blood sample: they all had Pap smear cytology consistent
with  an   HPV  infection.    Patients  with  both  laryngeal  and  gynecological  HPV
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infection had no specific HLA DQ profiles, when these were compared with those
of other Finnish Caucasians. The two patients suffering a laryngeal relapse had no
HPV 11 antibodies, and no patients had cytological features of HPV infection in
oral samples which were also negative for the general HPV primers in PCR.
A novel experimental model of laryngeal HPV infection (IV)
Of the 30 laryngeal papilloma tumor biopsies, 20 biopsies were not co-cultured with
PPLF-XR cells, with 19 of these lost during early passages. They did not grow on
either 3T3-XR or irradiated human embryonic skin fibroblasts (HES-XR), and a few
cultures were lost because of fungal infection. We failed to culture single biopsies
without feeders or in soft agarose. Moreover, some specimens were lost when
inhibition of the growth of accompanying fibroblasts on calcium-free growth
medium was attempted without success. Only once were HPV-positive laryngeal
papilloma cells able to grow until the fourth passage on 3T3-XR cells. We then
decided to culture all our biopsies on PPLF-XR cells.
Ten biopsies were cultured on PPLF-XR cells and five of them at least until the
fourth passage. The biopsy derived from normal-appearing laryngeal mucosa of the
esophageal carcinoma. patient with a widely spread disease was also cultured on
PPLF-XR cells, and grew successfully until the fourth passage. Of these monolayer
cell cultures, in situ hybridization was performed on those four which were later
transferred to grow on a collagen raft. These cultures showed persistence of
HPV-DNA-positive epithelial cells during the passages. When these epithelial cells
were transferred to allow growth on an organotypic growth base (collagen raft with
un-irradiated PPLF), they produced cytology with typical features (koilocytes,
dyskeratotic  cells,   and  parakeratosis)  of  a  laryngeal  papilloma  tumor.    In  situ
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hybridization, which was performed on sections of these collagen rafts, showed
that the epithelial cells had maintained the HPV genome.
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In this work we have studied adult-onset laryngeal papillomatosis from different
points of view which could relate to the prediction, course, and severity of the
disease, and created a novel experimental model of laryngeal HPV infection.
The manifestations of laryngeal HPV infection can be divided into three clinical
entities in which the role of the virus is more or less understood. First, the
asymptomatic presence of HPV DNA in macroscopically normal laryngeal mucosa
and in benign laryngeal lesions without a histology of papillomas is possible.
Second, HW DNA is sometimes detected in premalignant laryngeal lesions and in
laryngeal carcinomas without pre-existing laryngeal papillomatosis. Third, and the
clinically most important manifestation, is laryngeal papillomatosis which has also
the capacity for malignant transformation.
Laryngeal papillomatosis is not well characterized, and many basic problems may
emerge in the treatment of these patients. The means of transmission are in part
unknown, and the course of the disease is unpredictable and variable. The treatment
is based on surgery, although the etiology of the disease is viral. Alphainterferon,
which in our series of adult-onset patients was used in only 4/74 (5%), is the drug
most often used for treatment although it is expensive and it has side-effects. The
treatment takes up to 6 to 12 months and must be given in injections. For these
reasons, interferon is the drug of choice, mainly for children with an. aggressive,
relapsing disease. Long-term administration of alpha-interferon has led to complete
remission in approximately 40% and partial remission in an additional 40% of
patients (Leventhal et al., 1991). However, because alpha-interferon does not seem
to eliminate the latent virus (Steinberg et al., 1988), and relapses even decades later
are possible (Bergstrbm, 1982; Erisen et al., 1996), clinical studies in which the
curative effect of interferon could be investigated are difficult to carry out.
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Certain clinical and immunogenetic features predict the course of laryngeal
papillomatosis
The course of laryngeal papillomatosis varies greatly, and it would be of benefit to
recognize some predictive signs which could help us to focus the most attention on
patients who are at the greatest risk for frequent relapses. In some earlier reports
(Lindeberg and Elbrond, 1989; Quiney et al., 1989) solitary papillomas have been
signs of a good prognosis, but in our study this finding could not be confirmed. The
average number of laryngeal procedures performed for each patient was 5.4 during
the mean follow-up time of 6.2 years. Although the number may reflect not only the
severity of the disease but also the effectiveness of the surgery and the patient's
ability to accept hoarseness, it provides some information about the course of the
disease. The distribution of the number of laryngeal procedures required showed
that there were roughly two extreme groups of patients: those who needed only 1 to
2 laryngeal procedures for remission and those who had undergone more than 6
laryngeal procedures.
We have found two clinical signs at diagnosis which predict the relapsing course of
adult-onset laryngeal papillomatosis: patients' young age and a lesion reaching the
anterior parts of the vocal folds, the latter perhaps reflecting more the difficulties in
surgery in the anterior area than the true biological properties of the tumor. In line.
with these findings are the results of our HLA work. Those who had an increased
frequency of the protective DQB1*0501 allele and an HPV-negative latest laryngeal
papilloma specimen were older at diagnosis and had undergone fewer laryngeal
procedures than those whose latest laryngeal biopsies were HPV-positive. The
DQB1*0501 allele has been found to be protective in cervical cancer, another HPV-
related disease (Gregoire et al., 1994; Odunsi et al., 1996). This allele may help
patients eradicate the HPV genome, and in this way protect adult-onset papillorna
patients from  frequent  relapses.  Comparable data are available on  the clearance of
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hepatitis B virus: the HLA class II allele DRB1*1302 is associated with protection
against persistent hepatitis B virus infection (Thursz et al., 1995). However, these
HI'V-negative samples may also have contained some other HPV type(s) not
detectable by GP5+/6+ primers. It is possible that adult-onset laryngeal
papillomatosis is not a single entity but is divided into early-onset more-relapsing
and later-onset less-relapsing forms; cellular immunity may, in part, determine this
phenomenon. Although the data are somewhat conflicting, the most frequently
reported positive association with cervical carcinoma has been that of DQ3 antigen
or DQB1*03 alleles (Wank and Thomssen, 1991; Wank et al., 1993; Gregoire et al.,
1994), and the DQw3 phenotype has been shown to be enriched in a small series of
laryngeal papilloma patients, as well (Bonagura et al., 1994). However, in our series
we were unable to confirm the latter finding.
Laryngeal and genital HPV infection
Both laryngeal papillomatosis (Lack et al., 1980; Mounts et al., 1982; Gissmann et
al., 1983) and genital condylomas (Gissmann and zur Hausen, 1980; Gissmann et
al., 1984) are known to be caused by HW types 6 and 11. In the adult-onset form,
type 6 is found to be more common (Corbitt et al., 1988) than type 11, which was
the result in our study, as well. Moreover, in genital condylomas HPV 6 is more
common than HPV 11 (Greer et al., 1990). This similarity in HPV types detected in
laryngeal papillomas and in genital condylomas has brought forth the idea that
genital HW infection may be the source of the virus, and that the spread of the
infection could take place through orogenital contacts. Most of our patients had a
self-reported history of orogenital contacts (data not shown) but none of the nine
females whose mouth-wash and mouth-brush samples were studied had HPV
infection in their mouths as determined by PCR and cytology. Junctional areas of
cuboidal and cylindrical epithelium in both the vocal folds and in the uterine cervix
may  favor  the existence of  HW infection,  and the possible transient  HPV  load in
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saliva could infect the laryngeal epithelium more easily than that of the mouth. The
oral mucosa of women with genital HPV infection has been shown to be HPV-
positive by PCR in 23% of patients (Kellokoski et al., 1992) , which is comparable
with the prevalence of HPV infection in the macroscopically normal upper
respiratory mucosa in general.
Humoral immunity - a less important mechanism in defence against adult-onset
laryngeal papillomatosis?
Cellular immunity is of major importance for the clearance of infections caused by
HPVs, but humoral immune defects do not seem to predispose to HW infections
(Schiller and Okun, 1996). Genital HPV infection is known to elicit HPV antibody
production (Kirnbauer et al., 1994; Wikstrijm et al., 1995a; Eisemann et al., 1996;
Kjellberg et al., 1999), but HPV antibody production in laryngeal papillomatosis
had been examined previously only in small series of patients (Bonnez et al., 1994;
Christensen et al., 1992; Tachezy et al., 1994). What could have been expected is
either HPV 6 antibody production among the patients, because laryngeal papilloma
tumors are mostly caused by the HPV 6 virus type, or is a weak immune response in
general because HPVs most often induce latent infection or chronic disease
(Breitburd et al., 1996). However, only HPV 11 antibodies were more frequent in
patients than in controls, and more careful study showed female patients to have
HPV 11 antibodies more often than did male patients or female controls. It is
possible that these antibodies were of genital origin, since the presence of HPV
antibodies did not correlate with the clinical manifestations of laryngeal
papillomatosis, and because female patients had an increased prevalence of
cytological and histological signs of genital HPV infection. Unfortunately, because
we could not perform HPV PCR on Pap smears, the HPV genotypes of these genital
lesions remained unknown. Moreover, the serum antibody response did not correlate
with  the  HPV DNA  type found in the larynx,  although  the type-specificity of  the
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serological method based on VLPs has been demonstrated in many studies of genital
HPV infection (Kirnbauer et al., 1994; Wideroff et al., 1995; Kjellberg et al., 1999).
If antibodies against HPV 6, 11, and 16 VLPs had any clinical relevance, this should
have been discovered in this kind of large series and especially in male patients
because of the 2- to 4-fold male predominance in adult-onset disease. The lack of
correlation between HPV antibodies and the number of laryngeal procedures
performed or relapse detected in clinical examination both argue against the clinical
relevance of HPV antibodies.
Because the serum samples were taken on average 8 years after the laryngeal
samples, and no oral HW infection was detected in the females at the second visit, it
is possible that HPV antibodies induced by laryngeal infection might have been
present earlier but disappeared during follow-up. If so, such antibodies would be
less stable over time than antibodies to HPV 16 (af Geijersstam et al., 1998).
Stability over time of HPV 6 and 11 antibody levels has not been widely studied,
but a decline has been detected in antibody levels after clearance of HPV 6/11 DNA
(Wikström et al., 1995a). However, the lack of correlation between antibody
prevalences and either a current relapse in the larynx or the length of time-interval
between laryngeal biopsy and the serum sample-taking suggests an inability to
produce a response rather than poor stability over time.
It seems that viral structural proteins which induce the HPV antibodies measured in
our assay may not be commonly produced in laryngeal HPV infection. Our
preliminary results from immunohistochemistry (IHC) performed with L1- and L2-
specific rabbit antibodies (kindly provided by Dr. J. Dillner, Karolinska Institute,
Sweden) on sections of laryngeal tumor specimens and collagen rafts containing
laryngeal HPV-positive epithelial cells support this possibility. However, previous
data   on   capsid   antigen   production   in   laryngeal   papillomas   are  limited  and
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controversial (Lack et al., 1980; Mounts et al., 1982). In contrast, in genital
condylomas, capsid antigen production seem to be a common event (Sato et al.,
1986; Wilbur et al., 1988), and E6 antigens have also been detected (Tosi et al.,
1993).
Advantages of the novel experimental model of laryngeal HPV infection
Our method to culture laryngeal HIV-positive epithelial cells is based on the
supportive effects of PPLF fibroblasts on laryngeal HIV-infected cells. This is in
line with previous findings which emphasize the importance of the origin of
fibroblasts in modifying the epithelial phenotype in vitro, even when the epithelial
cells are malignant (Atula et al., 1997). Compared to the method of Steinberg et al.
(Steinberg et al., 1982; DiLorenzo, et al., 1992), our procedure offers the advantage
of maintaining the viral genome through passages in monolayer cell cultures, and
the multilayer on a collagen raft resembles well the cytology of a papilloma tumor.
Moreover, it is of benefit to multiply the HIV-infected cells in a monolayer, and if
needed, store them frozen until use in experiments. This novel method offers a
model of experimental laryngeal papilloma tumor which can be utilized when
studying, for example, the effects of interferons, other drugs, and hormones. At
present, alpha-interferon is the most widely accepted drug used for laryngeal
papillomatosis, but the results of the treatment are often unsatisfactory. If the
mechanisms of the action of interferon in HPV infection could be clarified in vitro,
efforts toward improving the properties of this drug could be guided in the right
direction. Moreover, investigating the effects of sex steroid hormones would also be
of interest, because of the known male predominance in adult-onset disease, and -
on the other hand - because of the direct action of these hormones on HPV-infected
epithelial cells (Monsonego et al., 1991). In our model, it is possible to investigate
the expression of different viral genes, which offers information, for example, about
the carcinogenic or virus-producing potential of the infection. Because collagen rafts
resemble  fresh tissue  specimens and  can  be handled  like them,  light and electron
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microscopy, and molecular biological and immunological tools such as PCR,
sequencing, ISH, and IHC can be used in the studies. However, culturing of
HPV-positive epithelial cells is not easy, and based on our preliminary results (data
not shown) it is possible that in our model, infectious viral particles are not
produced, although the viral genome was detected in sections of these collagen rafts
by ISH. Perhaps production of viral particles is a rare event even in vivo in laryngeal
papilloma tumors, because in electron microscopy studies viral particles are rarely
found (Svoboda et al., 1963; Cook et al., 1973), and in antibody assays serum HPV
antibodies against capsid proteins are infrequently detected in adult-onset patients.
Concluding remarks
Researchers who study laryngeal HPV infection face some major problems in their
work. Statistical significance is not easily established, because the disease is rare,
and the number of patients available is severely limited. Moreover, laryngeal tumor
biopsies cannot easily be taken without general anesthesia, and as we are dealing
with a sensitive voice-producing organ, only small biopsies may be obtained. The
impossibility of producing reasonable amounts of viral particles in vitro, and the
difficulty in culturing HPV-infected epithelial cells - which is related to the former
problem - make experimental studies of laryngeal HPV infection laborious. In this
work, a novel experimental model of laryngeal HPV infection is presented. Clinical
signs at diagnosis which predict a relapsing course and the role of immunogenetic
risk factors and humoral immunity in adult-onset disease are elucidated. Moreover,
connections between laryngeal and genital HIV infection have been investigated,
and it will be of interest to see how studies on genetic variation of the F1PV will
expand our knowledge on this issue.
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